Selected research
Industry Research
Gabexate Mesylate for Injection Industry Research Report 2026
Market perspective
The global Gabexate Mesylate for Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gabexate Mesylate for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gabexate Mesylate for Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gabexate Mesylate for Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gabexate Mesylate for Injection include Chongqing Pharscin Pharmaceutical Co., Ltd., Shanxi Pude Pharmaceutical, Medisan, Emeishan Tonghui Pharmaceutical and Chengdu Tiantai Mount Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gabexate Mesylate for Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gabexate Mesylate for Injection Market by Company
Chongqing Pharscin Pharmaceutical Co., Ltd.
Shanxi Pude Pharmaceutical
Medisan
Emeishan Tonghui Pharmaceutical
Chengdu Tiantai Mount Pharmaceutical
Gabexate Mesylate for Injection Segment by Type
120mg
160mg
40mg
80mg
Gabexate Mesylate for Injection Segment by Application
Hospital Pharmacy
Retail Pharmacy
Others
Gabexate Mesylate for Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gabexate Mesylate for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gabexate Mesylate for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gabexate Mesylate for Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gabexate Mesylate for Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gabexate Mesylate for Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gabexate Mesylate for Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 120mg
- 160mg
- 40mg
- 80mg
Applications
- Hospital Pharmacy
- Retail Pharmacy
- Others
Companies covered
- Chongqing Pharscin Pharmaceutical Co., Ltd.
- Shanxi Pude Pharmaceutical
- Medisan
- Emeishan Tonghui Pharmaceutical
- Chengdu Tiantai Mount Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gabexate Mesylate for Injection Market Size (2021-2032)
- 2.2.2 Global Gabexate Mesylate for Injection Sales (2021-2032)
- 2.2.3 Global Gabexate Mesylate for Injection Market Average Price (2021-2032)
- 2.3 Gabexate Mesylate for Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 120mg
- 2.3.3 160mg
- 2.3.4 40mg
- 2.3.5 80mg
- 2.4 Gabexate Mesylate for Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacy
- 2.4.3 Retail Pharmacy
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gabexate Mesylate for Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gabexate Mesylate for Injection Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Gabexate Mesylate for Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Gabexate Mesylate for Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Gabexate Mesylate for Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gabexate Mesylate for Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gabexate Mesylate for Injection, Product Type & Application
- 3.8 Global Manufacturers of Gabexate Mesylate for Injection, Established Date
- 3.9 Global Gabexate Mesylate for Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chongqing Pharscin Pharmaceutical Co., Ltd.
- 4.1.1 Chongqing Pharscin Pharmaceutical Co., Ltd. Company Information
- 4.1.2 Chongqing Pharscin Pharmaceutical Co., Ltd. Business Overview
- 4.1.3 Chongqing Pharscin Pharmaceutical Co., Ltd. Gabexate Mesylate for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chongqing Pharscin Pharmaceutical Co., Ltd. Gabexate Mesylate for Injection Product Portfolio
- 4.1.5 Chongqing Pharscin Pharmaceutical Co., Ltd. Recent Developments
- 4.2 Shanxi Pude Pharmaceutical
- 4.2.1 Shanxi Pude Pharmaceutical Company Information
- 4.2.2 Shanxi Pude Pharmaceutical Business Overview
- 4.2.3 Shanxi Pude Pharmaceutical Gabexate Mesylate for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanxi Pude Pharmaceutical Gabexate Mesylate for Injection Product Portfolio
- 4.2.5 Shanxi Pude Pharmaceutical Recent Developments
- 4.3 Medisan
- 4.3.1 Medisan Company Information
- 4.3.2 Medisan Business Overview
- 4.3.3 Medisan Gabexate Mesylate for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Medisan Gabexate Mesylate for Injection Product Portfolio
- 4.3.5 Medisan Recent Developments
- 4.4 Emeishan Tonghui Pharmaceutical
- 4.4.1 Emeishan Tonghui Pharmaceutical Company Information
- 4.4.2 Emeishan Tonghui Pharmaceutical Business Overview
- 4.4.3 Emeishan Tonghui Pharmaceutical Gabexate Mesylate for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Emeishan Tonghui Pharmaceutical Gabexate Mesylate for Injection Product Portfolio
- 4.4.5 Emeishan Tonghui Pharmaceutical Recent Developments
- 4.5 Chengdu Tiantai Mount Pharmaceutical
- 4.5.1 Chengdu Tiantai Mount Pharmaceutical Company Information
- 4.5.2 Chengdu Tiantai Mount Pharmaceutical Business Overview
- 4.5.3 Chengdu Tiantai Mount Pharmaceutical Gabexate Mesylate for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Chengdu Tiantai Mount Pharmaceutical Gabexate Mesylate for Injection Product Portfolio
- 4.5.5 Chengdu Tiantai Mount Pharmaceutical Recent Developments
5 Global Gabexate Mesylate for Injection Market Scenario by Region
- 5.1 Global Gabexate Mesylate for Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gabexate Mesylate for Injection Sales by Region: 2021-2032
- 5.2.1 Global Gabexate Mesylate for Injection Sales by Region: 2021-2026
- 5.2.2 Global Gabexate Mesylate for Injection Sales by Region: 2027-2032
- 5.3 Global Gabexate Mesylate for Injection Revenue by Region: 2021-2032
- 5.3.1 Global Gabexate Mesylate for Injection Revenue by Region: 2021-2026
- 5.3.2 Global Gabexate Mesylate for Injection Revenue by Region: 2027-2032
- 5.4 North America Gabexate Mesylate for Injection Market Facts & Figures by Country
- 5.4.1 North America Gabexate Mesylate for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gabexate Mesylate for Injection Sales by Country (2021-2032)
- 5.4.3 North America Gabexate Mesylate for Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Gabexate Mesylate for Injection Market Facts & Figures by Country
- 5.5.1 Europe Gabexate Mesylate for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gabexate Mesylate for Injection Sales by Country (2021-2032)
- 5.5.3 Europe Gabexate Mesylate for Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Gabexate Mesylate for Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gabexate Mesylate for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gabexate Mesylate for Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gabexate Mesylate for Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gabexate Mesylate for Injection Market Facts & Figures by Country
- 5.7.1 South America Gabexate Mesylate for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gabexate Mesylate for Injection Sales by Country (2021-2032)
- 5.7.3 South America Gabexate Mesylate for Injection Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Gabexate Mesylate for Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gabexate Mesylate for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gabexate Mesylate for Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gabexate Mesylate for Injection Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Gabexate Mesylate for Injection Sales by Type (2021-2032)
- 6.1.1 Global Gabexate Mesylate for Injection Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Gabexate Mesylate for Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Gabexate Mesylate for Injection Revenue by Type (2021-2032)
- 6.2.1 Global Gabexate Mesylate for Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gabexate Mesylate for Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Gabexate Mesylate for Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gabexate Mesylate for Injection Sales by Application (2021-2032)
- 7.1.1 Global Gabexate Mesylate for Injection Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Gabexate Mesylate for Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Gabexate Mesylate for Injection Revenue by Application (2021-2032)
- 7.2.1 Global Gabexate Mesylate for Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gabexate Mesylate for Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Gabexate Mesylate for Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gabexate Mesylate for Injection Value Chain Analysis
- 8.1.1 Gabexate Mesylate for Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gabexate Mesylate for Injection Production Mode & Process
- 8.2 Gabexate Mesylate for Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gabexate Mesylate for Injection Distributors
- 8.2.3 Gabexate Mesylate for Injection Customers
9 Global Gabexate Mesylate for Injection Analyzing Market Dynamics
- 9.1 Gabexate Mesylate for Injection Industry Trends
- 9.2 Gabexate Mesylate for Injection Industry Drivers
- 9.3 Gabexate Mesylate for Injection Industry Opportunities and Challenges
- 9.4 Gabexate Mesylate for Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst